{"protocolSection":{"identificationModule":{"nctId":"NCT01703091","orgStudyIdInfo":{"id":"14658"},"secondaryIdInfos":[{"id":"I4T-JE-JVCG","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer","officialTitle":"A Randomized, Double-Blind, Phase 2 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy"},"statusModule":{"statusVerifiedDate":"2019-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-12"},"primaryCompletionDateStruct":{"date":"2014-12","type":"ACTUAL"},"completionDateStruct":{"date":"2016-07","type":"ACTUAL"},"studyFirstSubmitDate":"2012-10-05","studyFirstSubmitQcDate":"2012-10-05","studyFirstPostDateStruct":{"date":"2012-10-10","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-12-14","resultsFirstSubmitQcDate":"2015-12-14","resultsFirstPostDateStruct":{"date":"2016-01-20","type":"ESTIMATED"},"lastUpdateSubmitDate":"2019-09-10","lastUpdatePostDateStruct":{"date":"2019-09-30","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the effects of ramucirumab in combination with docetaxel in participants with Stage IV non-small cell lung cancer who have had disease progression during or after one prior first-line platinum-based chemotherapy with or without maintenance therapy for advanced/metastatic disease."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer Metastatic"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":197,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Ramucirumab plus Docetaxel","type":"EXPERIMENTAL","description":"Ramucirumab 10 milligram per kilogram (mg/kg) on Day 1 of every 21 day cycle, administered as an intravenous (IV) infusion over approximately 60 minutes. Docetaxel 60 milligram per square meter (mg/m2) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.","interventionNames":["Drug: Ramucirumab","Drug: Docetaxel"]},{"label":"Placebo plus Docetaxel","type":"PLACEBO_COMPARATOR","description":"Placebo (administered at a volume equivalent to a dose of milligram per kilogram (mg/kg)) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes. Docetaxel 60 mg/m2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.","interventionNames":["Drug: Placebo","Drug: Docetaxel"]}],"interventions":[{"type":"DRUG","name":"Ramucirumab","description":"Administered IV","armGroupLabels":["Ramucirumab plus Docetaxel"],"otherNames":["LY 3009806","IMC-1121B","Cyramza®"]},{"type":"DRUG","name":"Placebo","description":"Administered IV","armGroupLabels":["Placebo plus Docetaxel"]},{"type":"DRUG","name":"Docetaxel","description":"Administered IV","armGroupLabels":["Placebo plus Docetaxel","Ramucirumab plus Docetaxel"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-Free Survival (PFS)","description":"PFS was defined as the time from baseline until measured progressive disease (PD) or death from any cause, whichever is first. According to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), PD was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the 20% relative increase, the sum must have also demonstrated an absolute increase of at least 5 millimeters (mm). The appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions was also considered progression. Participants without objectively determined PD, who were alive at the end of the follow-up period (or lost to follow-up), were censored on the date of the participant's last complete radiographic tumor assessment; if no baseline or post-baseline radiologic assessment was available, the participant was censored at the date of randomization.","timeFrame":"Baseline to Measured Progressive Disease or Death from Any Cause (Up to 21 Months)"}],"secondaryOutcomes":[{"measure":"Overall Survival (OS)","description":"OS was defined as time from baseline to the date of death from any cause. Participants who were alive at the end of the follow-up period (or lost to follow-up) were censored on the last date the participant was known to be alive.","timeFrame":"Baseline to Death from Any Cause (Up to 28 Months)"},{"measure":"Percentage of Participants Who Achieved Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) [Objective Tumor Response Rate (ORR)]","description":"Participants achieved an objective response if they had a best overall response of complete response (CR) or partial response (PR). According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \\<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal \\[ULN\\]); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. The percentage of participants who achieved an objective response equals (number of participants with CR or PR)/(number of participants assessed)\\*100.","timeFrame":"Baseline to Measured Progressive Disease or Participant Stops Study (Up to 97 Weeks)"},{"measure":"Percentage of Participants Who Achieved Best Overall Disease Response of CR, PR or Stable Disease (SD) [Disease Control Rate (DCR)]","description":"Participants achieved disease control if they had a best overall response of PR, CR or SD. According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \\<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal \\[ULN\\]); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. SD was neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started. The percentage of participants who achieved disease control equals (number of participants with CR, PR, or SD)/(number of participants assessed)\\*100.","timeFrame":"Baseline to Measured Progressive Disease or Participant Stopped Study (Up to 97 Weeks)"},{"measure":"Change From Baseline in European Quality of Life Questionnaire - 5 Dimension (EQ-5D) Index Score","description":"The EQ-5D is a quality-of-life instrument which allowed participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a scale from 1 to 3 (no problem, some problems, and extreme problems, respectively). These combinations of attributes were converted into a weighted Health State Index score according to a United Kingdom population-based algorithm; the possible values for the Health State Index score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).","timeFrame":"Baseline, Day 21 Each Cycle (Cycle = 21 Days) and 30-Day Follow Up (Up to 97 Weeks)"},{"measure":"Change From Baseline in Lung Cancer Symptom Scale (LCSS)","description":"The participant-reported LCSS was a 9-item questionnaire. Six items were symptom-specific measures for lung cancer (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain), and 3 summation items described total symptomatic distress, interference with activity level, and global quality of life. Participant responses to each item were measured using a visual analog scale (VAS) from 0 (best outcome) to 100 (worst outcome). The Average Symptom Burden Index (ASBI) was the mean of the 6 symptom-specific items in the LCSS. The Total LCSS was the mean of all 9 LCSS items. Maximum improvement in LCSS scores, ASBI, and Total LCSS score was the largest decrease from baseline for each variable, which was the smallest (most negative or smallest positive) non-missing value among all change from baseline values for each variable.","timeFrame":"Baseline to Measured Progressive Disease or Participant Stopped Study (up to 97 weeks)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Non-Small Cell Lung Cancer disease\n* Clinical stage IV or recurrent disease\n* One prior first-line platinum-based chemotherapy regimen with or without maintenance therapy\n* For Non-Small Cell Lung Cancer (NSCLC) tumors other than squamous cell histology, the epidermal growth factor receptor (EGFR) mutation status is known prior to randomization\n* For participants with activating epidermal growth factor receptor (EGFR) mutation only, prior epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI) monotherapy (only one regimen in the setting of single use) should be utilized\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1\n* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version RECIST version 1.1\n* Adequate organ function\n* Estimated life expectancy of at least 3 months.\n\nExclusion Criteria:\n\n* Have undergone major surgery within 28 days prior to randomization or have planned major surgery during study treatment\n* Receiving concurrent treatment with other anticancer therapy\n* Central nervous system disease other than stable and treated brain metastasis\n* Has major blood vessel invasion or encasement by cancer\n* Has intratumor cavitation\n* Has a history of uncontrolled thrombotic disorder\n* Is receiving therapeutic anticoagulation with drugs\n* Is receiving chronic therapy with nonsteroidal anti-inflammatory drugs\n* Has a history of hemoptysis within 2 months prior to randomization\n* Has clinically relevant congestive heart failure\n* Has experienced any arterial thromboembolic event\n* Has uncontrolled arterial hypertension\n* Has had a serious or nonhealing wound or, ulcer\n* Has significant existing conditions","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Aichi","zip":"464-8681","country":"Japan","geoPoint":{"lat":32.51879,"lon":130.62158}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chiba","zip":"277 8577","country":"Japan","geoPoint":{"lat":35.6,"lon":140.11667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ehime","zip":"791-0280","country":"Japan"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fukuoka","zip":"830-0011","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hokkaido","zip":"060-8648","country":"Japan"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hyōgo","zip":"673-8558","country":"Japan","geoPoint":{"lat":43.36667,"lon":144.43333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ishikawa","zip":"920-8641","country":"Japan","geoPoint":{"lat":26.42333,"lon":127.82139}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kanagawa","zip":"236-0051","country":"Japan","geoPoint":{"lat":37.58333,"lon":139.91667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Miyagi","zip":"980-8574","country":"Japan","geoPoint":{"lat":26.62566,"lon":128.18236}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Okayama","zip":"700-8558","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Osaka","zip":"589-8511","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Saitama","zip":"362-0806","country":"Japan","geoPoint":{"lat":35.90807,"lon":139.65657}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Shizuoka","zip":"411-8777","country":"Japan","geoPoint":{"lat":34.98333,"lon":138.38333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tokyo","zip":"135-8550","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Yamaguchi","zip":"755-0241","country":"Japan","geoPoint":{"lat":34.18333,"lon":131.46667}}]},"referencesModule":{"references":[{"pmid":"34795131","type":"DERIVED","citation":"Mitani S, Chen Y, Inoue K, Mori J, Gao L, Long A, Wakabayashi S. Clinical Impact of a Shortened Infusion Duration of Ramucirumab in Japanese Patients -A Model-Based Approach. Gan To Kagaku Ryoho. 2021 Nov;48(11):1381-1387."},{"pmid":"27565938","type":"DERIVED","citation":"Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N, Nishio M, Ohe Y, Koue T, Nakamura T, Enatsu S, Lee P, Ferry D, Tamura T, Nakagawa K. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer. 2016 Sep;99:186-93. doi: 10.1016/j.lungcan.2016.07.019. Epub 2016 Jul 18."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.","timeFrame":"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.","accessCriteria":"A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.","url":"https://vivli.org/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Study completion was defined as death due to any cause or disease progression.","groups":[{"id":"FG000","title":"Ramucirumab Plus Docetaxel","description":"Ramucirumab 10 milligrams/kilogram (mg/kg) administered as an intravenous (IV) infusion over approximately 60 minutes on Day 1 of every 21-day cycle. Docetaxel 60 milligrams/square meter (mg/m2) administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle."},{"id":"FG001","title":"Placebo Plus Docetaxel","description":"Placebo administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle. Docetaxel 60 mg/m2 administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"98"},{"groupId":"FG001","numSubjects":"99"}]},{"type":"Received at Least One Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"94"},{"groupId":"FG001","numSubjects":"98"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"89"},{"groupId":"FG001","numSubjects":"95"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"4"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants who had received at least one dose of study drug.","groups":[{"id":"BG000","title":"Ramucirumab + Docetaxel","description":"Ramucirumab 10 mg/kg administered as an intravenous (IV) infusion over approximately 60 minutes on Day 1 of every 21-day cycle. Docetaxel 60 mg/m2 administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle."},{"id":"BG001","title":"Placebo + Docetaxel","description":"Placebo administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle. Docetaxel 60 mg/m2 administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"94"},{"groupId":"BG001","value":"98"},{"groupId":"BG002","value":"192"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63.9","lowerLimit":"29","upperLimit":"78"},{"groupId":"BG001","value":"64.1","lowerLimit":"27","upperLimit":"79"},{"groupId":"BG002","value":"64","lowerLimit":"27","upperLimit":"79"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"55"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"71"},{"groupId":"BG002","value":"137"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"94"},{"groupId":"BG001","value":"98"},{"groupId":"BG002","value":"192"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"Japan","categories":[{"measurements":[{"groupId":"BG000","value":"94"},{"groupId":"BG001","value":"98"},{"groupId":"BG002","value":"192"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS)","description":"PFS was defined as the time from baseline until measured progressive disease (PD) or death from any cause, whichever is first. According to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), PD was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the 20% relative increase, the sum must have also demonstrated an absolute increase of at least 5 millimeters (mm). The appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions was also considered progression. Participants without objectively determined PD, who were alive at the end of the follow-up period (or lost to follow-up), were censored on the date of the participant's last complete radiographic tumor assessment; if no baseline or post-baseline radiologic assessment was available, the participant was censored at the date of randomization.","populationDescription":"Full Analysis Set (FAS) population: All randomized participants who received at least one dose of study drug and whose prior therapy did not include EGFR-TKI monotherapy. The number of censored participant data for ramucirumab and placebo is 13 and 9, respectively.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline to Measured Progressive Disease or Death from Any Cause (Up to 21 Months)","groups":[{"id":"OG000","title":"Ramucirumab + Docetaxel","description":"Ramucirumab 10 mg/kg administered as an intravenous (IV) infusion over approximately 60 minutes on Day 1 of every 21-day cycle. Docetaxel 60 mg/m2 administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle."},{"id":"OG001","title":"Placebo + Docetaxel","description":"Placebo administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle. Docetaxel 60 mg/m2 administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"81"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.22","lowerLimit":"3.52","upperLimit":"6.97"},{"groupId":"OG001","value":"4.21","lowerLimit":"2.83","upperLimit":"5.62"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as time from baseline to the date of death from any cause. Participants who were alive at the end of the follow-up period (or lost to follow-up) were censored on the last date the participant was known to be alive.","populationDescription":"FAS population: All randomized participants who received at least one dose of study drug and whose prior therapy did not include EGFR-TKI monotherapy. The number of censored participant data for ramucirumab and placebo is 36 and 35, respectively.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline to Death from Any Cause (Up to 28 Months)","groups":[{"id":"OG000","title":"Ramucirumab + Docetaxel","description":"Ramucirumab 10 mg/kg administered as an intravenous (IV) infusion over approximately 60 minutes on Day 1 of every 21-day cycle. Docetaxel 60 mg/m2 administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle."},{"id":"OG001","title":"Placebo + Docetaxel","description":"Placebo administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle. Docetaxel 60 mg/m2 administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"81"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.15","lowerLimit":"12.45","upperLimit":"26.55"},{"groupId":"OG001","value":"14.65","lowerLimit":"11.93","upperLimit":"24.44"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) [Objective Tumor Response Rate (ORR)]","description":"Participants achieved an objective response if they had a best overall response of complete response (CR) or partial response (PR). According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \\<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal \\[ULN\\]); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. The percentage of participants who achieved an objective response equals (number of participants with CR or PR)/(number of participants assessed)\\*100.","populationDescription":"FAS population: All randomized participants who received at least one dose of study drug and whose prior therapy did not include EGFR-TKI monotherapy.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"Baseline to Measured Progressive Disease or Participant Stops Study (Up to 97 Weeks)","groups":[{"id":"OG000","title":"Ramucirumab + Docetaxel","description":"Ramucirumab 10 mg/kg administered as an intravenous (IV) infusion over approximately 60 minutes on Day 1 of every 21-day cycle. Docetaxel 60 mg/m2 administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle."},{"id":"OG001","title":"Placebo + Docetaxel","description":"Placebo administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle. Docetaxel 60 mg/m2 administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"81"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","lowerLimit":"19.1","upperLimit":"40.5"},{"groupId":"OG001","value":"18.5","lowerLimit":"10.8","upperLimit":"28.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Best Overall Disease Response of CR, PR or Stable Disease (SD) [Disease Control Rate (DCR)]","description":"Participants achieved disease control if they had a best overall response of PR, CR or SD. According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \\<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal \\[ULN\\]); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. SD was neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started. The percentage of participants who achieved disease control equals (number of participants with CR, PR, or SD)/(number of participants assessed)\\*100.","populationDescription":"FAS population: All randomized participants who received at least one dose of study drug and whose prior therapy did not include EGFR-TKI monotherapy.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"Baseline to Measured Progressive Disease or Participant Stopped Study (Up to 97 Weeks)","groups":[{"id":"OG000","title":"Ramucirumab + Docetaxel","description":"Ramucirumab 10 mg/kg administered as an intravenous (IV) infusion over approximately 60 minutes on Day 1 of every 21-day cycle. Docetaxel 60 mg/m2 administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle."},{"id":"OG001","title":"Placebo + Docetaxel","description":"Placebo administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle. Docetaxel 60 mg/m2 administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"81"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","lowerLimit":"68.1","upperLimit":"87.5"},{"groupId":"OG001","value":"70.4","lowerLimit":"59.2","upperLimit":"80.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in European Quality of Life Questionnaire - 5 Dimension (EQ-5D) Index Score","description":"The EQ-5D is a quality-of-life instrument which allowed participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a scale from 1 to 3 (no problem, some problems, and extreme problems, respectively). These combinations of attributes were converted into a weighted Health State Index score according to a United Kingdom population-based algorithm; the possible values for the Health State Index score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).","populationDescription":"FAS population: All randomized participants who received at least one dose of study drug and whose prior therapy did not include EGFR-TKI monotherapy.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units on a Scale","timeFrame":"Baseline, Day 21 Each Cycle (Cycle = 21 Days) and 30-Day Follow Up (Up to 97 Weeks)","groups":[{"id":"OG000","title":"Ramucirumab + Docetaxel","description":"Ramucirumab 10 mg/kg administered as an intravenous (IV) infusion over approximately 60 minutes on Day 1 of every 21-day cycle. Docetaxel 60 mg/m2 administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle."},{"id":"OG001","title":"Placebo + Docetaxel","description":"Placebo administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle. Docetaxel 60 mg/m2 administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"81"}]}],"classes":[{"title":"Cycle 1 (n = 69, 77)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.024","spread":"0.1928"},{"groupId":"OG001","value":"-0.007","spread":"0.1918"}]}]},{"title":"Cycle 2 (n = 62, 66)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.021","spread":"0.2190"},{"groupId":"OG001","value":"0.006","spread":"0.1961"}]}]},{"title":"Cycle 3 (n = 48, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.010","spread":"0.2324"},{"groupId":"OG001","value":"-0.005","spread":"0.1891"}]}]},{"title":"Cycle 4 (n = 40, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"0.015","spread":"0.1683"},{"groupId":"OG001","value":"-0.026","spread":"0.1610"}]}]},{"title":"Cycle 5 (n = 32, 40)","categories":[{"measurements":[{"groupId":"OG000","value":"0.000","spread":"0.2280"},{"groupId":"OG001","value":"-0.012","spread":"0.1433"}]}]},{"title":"Cycle 6 (n = 28, 36)","categories":[{"measurements":[{"groupId":"OG000","value":"0.035","spread":"0.1741"},{"groupId":"OG001","value":"-0.005","spread":"0.1409"}]}]},{"title":"Cycle 7 (n = 25 ,31)","categories":[{"measurements":[{"groupId":"OG000","value":"0.002","spread":"0.1857"},{"groupId":"OG001","value":"-0.039","spread":"0.1282"}]}]},{"title":"Cycle 8 (n = 23, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.053","spread":"0.1750"},{"groupId":"OG001","value":"-0.071","spread":"0.1800"}]}]},{"title":"30-Day Follow Up (n= 56, 70)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.102","spread":"0.2209"},{"groupId":"OG001","value":"-0.132","spread":"0.3344"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lung Cancer Symptom Scale (LCSS)","description":"The participant-reported LCSS was a 9-item questionnaire. Six items were symptom-specific measures for lung cancer (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain), and 3 summation items described total symptomatic distress, interference with activity level, and global quality of life. Participant responses to each item were measured using a visual analog scale (VAS) from 0 (best outcome) to 100 (worst outcome). The Average Symptom Burden Index (ASBI) was the mean of the 6 symptom-specific items in the LCSS. The Total LCSS was the mean of all 9 LCSS items. Maximum improvement in LCSS scores, ASBI, and Total LCSS score was the largest decrease from baseline for each variable, which was the smallest (most negative or smallest positive) non-missing value among all change from baseline values for each variable.","populationDescription":"FAS population: All randomized participants who received at least one dose of study drug and whose prior therapy did not include EGFR-TKI monotherapy.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Millimeter","timeFrame":"Baseline to Measured Progressive Disease or Participant Stopped Study (up to 97 weeks)","groups":[{"id":"OG000","title":"Ramucirumab + Docetaxel","description":"Ramucirumab 10 mg/kg administered as an intravenous (IV) infusion over approximately 60 minutes on Day 1 of every 21-day cycle. Docetaxel 60 mg/m2 administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle."},{"id":"OG001","title":"Placebo + Docetaxel","description":"Placebo administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle. Docetaxel 60 mg/m2 administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"81"}]}],"classes":[{"title":"Loss of Appetite (n=73, 79)","categories":[{"measurements":[{"groupId":"OG000","value":"-12.5","spread":"26.23"},{"groupId":"OG001","value":"-16.2","spread":"21.45"}]}]},{"title":"Fatigue (n=73, 80)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.9","spread":"25.38"},{"groupId":"OG001","value":"-7.8","spread":"23.59"}]}]},{"title":"Cough (n=73, 80)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":"23.10"},{"groupId":"OG001","value":"-18.3","spread":"23.83"}]}]},{"title":"Dyspnea (n=73, 80)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"23.09"},{"groupId":"OG001","value":"-8.7","spread":"20.16"}]}]},{"title":"Hemoptysis (n=73, 80)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"12.83"},{"groupId":"OG001","value":"-3.7","spread":"17.25"}]}]},{"title":"Pain (n=73, 80)","categories":[{"measurements":[{"groupId":"OG000","value":"-9.6","spread":"23.66"},{"groupId":"OG001","value":"-9.0","spread":"21.52"}]}]},{"title":"Overall Symptoms (n=73, 80)","categories":[{"measurements":[{"groupId":"OG000","value":"-7.1","spread":"26.10"},{"groupId":"OG001","value":"-11.5","spread":"19.83"}]}]},{"title":"Interference with Activity Level (n=73, 80)","categories":[{"measurements":[{"groupId":"OG000","value":"-8.4","spread":"25.84"},{"groupId":"OG001","value":"-11.9","spread":"21.98"}]}]},{"title":"Quality of Life (n=73, 80)","categories":[{"measurements":[{"groupId":"OG000","value":"-11.7","spread":"28.06"},{"groupId":"OG001","value":"-12.7","spread":"21.06"}]}]},{"title":"ASBI (n=73, 79)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.82","spread":"14.93"},{"groupId":"OG001","value":"-6.93","spread":"12.06"}]}]},{"title":"Total LCSS (n=73, 79)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.20","spread":"15.64"},{"groupId":"OG001","value":"-7.13","spread":"11.74"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","description":"All randomized participants who received at least one dose of study drug.","eventGroups":[{"id":"EG000","title":"Ramucirumab + Docetaxel","description":"Ramucirumab 10 mg/kg administered as an intravenous (IV) infusion over approximately 60 minutes on Day 1 of every 21-day cycle. Docetaxel 60 mg/m2 administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle.","seriousNumAffected":30,"seriousNumAtRisk":94,"otherNumAffected":94,"otherNumAtRisk":94},{"id":"EG001","title":"Placebo + Docetaxel","description":"Placebo administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle. Docetaxel 60 mg/m2 administered as an IV infusion over approximately 60 minutes on Day 1 of every 21-day cycle.","seriousNumAffected":31,"seriousNumAtRisk":98,"otherNumAffected":98,"otherNumAtRisk":98}],"seriousEvents":[{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":94},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":98}]},{"term":"Splenomegaly","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]},{"term":"Anorectal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Gastric ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]},{"term":"Ileus paralytic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Large intestine perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Hepatic cirrhosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]},{"term":"Bronchopulmonary aspergillosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":98}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Chondrocalcinosis pyrophosphate","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Lymphangiosis carcinomatosa","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]},{"term":"Metastases to meninges","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":94},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":98}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]},{"term":"Bladder disorder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":94},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":98}]},{"term":"Lung disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Obstructive airways disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]},{"term":"Pleurisy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":94},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":98}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":60,"numAffected":37,"numAtRisk":94},{"groupId":"EG001","numEvents":68,"numAffected":41,"numAtRisk":98}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":26,"numAtRisk":94},{"groupId":"EG001","numEvents":17,"numAffected":15,"numAtRisk":98}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":13,"numAtRisk":94},{"groupId":"EG001","numEvents":63,"numAffected":24,"numAtRisk":98}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":17,"numAtRisk":94},{"groupId":"EG001","numEvents":70,"numAffected":30,"numAtRisk":98}]},{"term":"Eye discharge","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":94},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":98}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":94},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":98}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":94},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":98}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":94},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":98}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":15,"numAtRisk":94},{"groupId":"EG001","numEvents":36,"numAffected":28,"numAtRisk":98}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":50,"numAffected":31,"numAtRisk":94},{"groupId":"EG001","numEvents":50,"numAffected":23,"numAtRisk":98}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":34,"numAtRisk":94},{"groupId":"EG001","numEvents":52,"numAffected":39,"numAtRisk":98}]},{"term":"Periodontal disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":92,"numAffected":50,"numAtRisk":94},{"groupId":"EG001","numEvents":41,"numAffected":31,"numAtRisk":98}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":14,"numAtRisk":94},{"groupId":"EG001","numEvents":31,"numAffected":22,"numAtRisk":98}]},{"term":"Face oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":15,"numAtRisk":94},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":98}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":45,"numAffected":29,"numAtRisk":94},{"groupId":"EG001","numEvents":47,"numAffected":25,"numAtRisk":98}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":97,"numAffected":43,"numAtRisk":94},{"groupId":"EG001","numEvents":85,"numAffected":47,"numAtRisk":98}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":34,"numAtRisk":94},{"groupId":"EG001","numEvents":33,"numAffected":28,"numAtRisk":98}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":54,"numAffected":31,"numAtRisk":94},{"groupId":"EG001","numEvents":45,"numAffected":26,"numAtRisk":98}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":94},{"groupId":"EG001","numEvents":15,"numAffected":5,"numAtRisk":98}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":94},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":98}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":94},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":98}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":94},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":98}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":94},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":98}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":94},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":98}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":94},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":98}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":9,"numAtRisk":94},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":98}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":15,"numAtRisk":94},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":98}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":19,"numAtRisk":94},{"groupId":"EG001","numEvents":12,"numAffected":6,"numAtRisk":98}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":94},{"groupId":"EG001","numEvents":11,"numAffected":6,"numAtRisk":98}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":94},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":98}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":6,"numAtRisk":94},{"groupId":"EG001","numEvents":43,"numAffected":11,"numAtRisk":98}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":281,"numAffected":73,"numAtRisk":94},{"groupId":"EG001","numEvents":219,"numAffected":69,"numAtRisk":98}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":22,"numAtRisk":94},{"groupId":"EG001","numEvents":22,"numAffected":14,"numAtRisk":98}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":94},{"groupId":"EG001","numEvents":12,"numAffected":9,"numAtRisk":98}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":261,"numAffected":73,"numAtRisk":94},{"groupId":"EG001","numEvents":226,"numAffected":68,"numAtRisk":98}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":90,"numAffected":54,"numAtRisk":94},{"groupId":"EG001","numEvents":92,"numAffected":51,"numAtRisk":98}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":44,"numAffected":29,"numAtRisk":94},{"groupId":"EG001","numEvents":32,"numAffected":21,"numAtRisk":98}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":94},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":98}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":18,"numAtRisk":94},{"groupId":"EG001","numEvents":27,"numAffected":14,"numAtRisk":98}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":94},{"groupId":"EG001","numEvents":17,"numAffected":13,"numAtRisk":98}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":19,"numAtRisk":94},{"groupId":"EG001","numEvents":26,"numAffected":18,"numAtRisk":98}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":94},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":98}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":25,"numAtRisk":94},{"groupId":"EG001","numEvents":34,"numAffected":26,"numAtRisk":98}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":12,"numAtRisk":94},{"groupId":"EG001","numEvents":22,"numAffected":16,"numAtRisk":98}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":94},{"groupId":"EG001","numEvents":27,"numAffected":27,"numAtRisk":98}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":17,"numAtRisk":94},{"groupId":"EG001","numEvents":21,"numAffected":18,"numAtRisk":98}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":28,"numAtRisk":94},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":98}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":94},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":98}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":94},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":98}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":90,"numAffected":46,"numAtRisk":94},{"groupId":"EG001","numEvents":21,"numAffected":18,"numAtRisk":98}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":94},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":98}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":8,"numAtRisk":94},{"groupId":"EG001","numEvents":24,"numAffected":9,"numAtRisk":98}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":94},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":98}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":94},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":98}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":63,"numAffected":63,"numAtRisk":94},{"groupId":"EG001","numEvents":62,"numAffected":61,"numAtRisk":98}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":94},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":98}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":17,"numAtRisk":94},{"groupId":"EG001","numEvents":17,"numAffected":17,"numAtRisk":98}]},{"term":"Nail discolouration","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":22,"numAtRisk":94},{"groupId":"EG001","numEvents":19,"numAffected":19,"numAtRisk":98}]},{"term":"Nail ridging","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":94},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":98}]},{"term":"Onychomadesis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":94},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":98}]},{"term":"Palmar-plantar erythrodysaesthesia syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":94},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":98}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":94},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":98}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":94},{"groupId":"EG001","numEvents":16,"numAffected":12,"numAtRisk":98}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":94},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":98}]},{"term":"Flushing","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":4,"numAtRisk":94},{"groupId":"EG001","numEvents":12,"numAffected":7,"numAtRisk":98}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":94},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":98}]},{"term":"Vasculitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":94},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":98}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"interventionBrowseModule":{"meshes":[{"id":"D000096662","term":"Ramucirumab"},{"id":"D000077143","term":"Docetaxel"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"}]}},"hasResults":true}